Management of hyperglycemia in type 2 diabetes: Evidence and uncertainty

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Esposito, Katherine ^a   Gentile, Sandro ^a   Candido, Riccardo ^b   De Micheli, Alberto ^c   Gallo, Marco ^d   Medea, Gerardo ^e   Ceriello, Antonio ^f,g  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ASS 1 Triestina   (Italy)

^c Ligurian Health Agency   (Italy)

^d Rianimazione ed Emergenze AOU Città della Salute e della Scienza   (Italy)

^e Società Italiana di Medicina Generale SIMG   (Italy)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT;

GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PERSONALIZED MEDICINE; UNCERTAINTY; ALGORITHM; COMPLICATION; DIABETES MELLITUS, TYPE 2; PATIENT CARE PLANNING; PRACTICE GUIDELINE;

ALGORITHMS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; OBESITY; PATIENT CARE PLANNING; PRACTICE GUIDELINES AS TOPIC;

EID: 84878214551     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-81     Document Type: Note

References (20)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94(3):311-321. 10.1016/j.diabres.2011.10.029, 22079683.
2. Ali MK, McKeever Bullard K, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013, 368(17):1613-1624. 10.1056/NEJMsa1213829, 23614587.
3. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378(9786):169-181. 10.1016/S0140-6736(11)60614-4, 21705072.
4. Wennberg J. On patient need, equity, supplier-induced demand, and the need to assess the outcome of common medical practice. Med Care 1985, 23(5):512-520. 10.1097/00005650-198505000-00012, 4010348.
5. Gianakos D. Accepting limits. Arch Intern Med 1998, 158(10):1059-1061. 10.1001/archinte.158.10.1059, 9605776.
6. Giugliano D, Esposito K. Clinical inertia as a clinical safeguard. JAMA 2011, 305(15):1591-1592. 10.1001/jama.2011.490, 21505139.
7. Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol 2013, 12(1):62. 10.1186/1475-2840-12-62, 3664601, 23574917.
8. Ceriello A, Gallo M, Armentano V, Perriello G, Gentile S, De Micheli A, Associazione Medici Diabetologi Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach. Diabetes Technol Ther 2012, 14(4):373-378. 10.1089/dia.2011.0233, 22216963, Associazione Medici Diabetologi.
9. Italian Association of Medical Diabetologists AMD Personalisation of therapy in type 2 diabetes 2013, http://www.aemmedi.it/algoritmi_it_2013, Accessed 1 June 2013, Italian Association of Medical Diabetologists AMD.
10. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009, 15(9):728-740.
11. Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes. Practical lessons from ACCORD and other cardiovascular trials. Diabetes Care 2012, 35(10):2100-2107. 10.2337/dc12-0650, 22996182.
12. World Health Organization 2013, Fact Sheet 311, http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 1 June 2013, World Health Organization.
13. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289(14):1799-1804. 10.1001/jama.289.14.1799, 12684358.
14. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771. 10.1136/bmj.d7771, 3256253, 22236411.
15. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
16. Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169. 10.1136/bmj.d4169, 3144314, 21791495.
17. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011, 343:d6898. 10.1136/bmj.d6898, 3223424, 22115901.
18. Esposito K, Ceriello A, Giugliano D. Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?. Endocrine 2013, Mar 12. http://link.springer.com/article/10.1007%2Fs12020-013-9918-x.
19. El-Gayar O, Timsina P, Nawar N, Eid W. Mobile applications for diabetes self-management: status and potential. J Diabetes Sci Technol 2013, 7(1):247-262.
20. Tang PC, Overhage JM, Chan AS, Brown NL, Aghighi B, Entwistle MP, Hui SL, Hyde SM, Klieman LH, Mitchell CJ, Perkins AJ, Qureshi LS, Waltimyer TA, Winters LJ, Young CY. Online disease management of diabetes: Engaging and Motivating Patients Online With Enhanced Resources-Diabetes (EMPOWER-D), a randomized controlled trial. J Am Med Inform Assoc 2013, 20(3):526-534. 10.1136/amiajnl-2012-001263, 23171659.